NCT02320435
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
At risk: Primary completion moved at least 2 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 110 versions: 37 with changes below, 13 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 15 words
- Primary and study completion pushed from Dec 31, 2026 to Mar 28, 2027
- Site details revised at 3 of 62 sites
- Minor Study sites: 61 to 62v109
- Minor Study sites: 59 to 61v108
- Minor Study sites: 61 to 59v106
- Notable Primary and study completion dates: May 31, 2026 to Dec 31, 2026
- Study sites: 62 to 61
Show 32 earlier versionsHide 32 earlier versions
- Minor Primary and study completion dates: Dec 31, 2025 to May 31, 2026
- Study sites revised (62)
- Minor Study sites: 63 to 62v101
- Minor Study sites: 62 to 63v100
- Minor Site details revised at 1 of 62 sitesv95
- Minor Study sites revised (62)v94
- Notable Primary and study completion dates: May 31, 2024 to Dec 31, 2025
- Enrollment target: 153 to 154
- Study sites revised (62)
- Minor Site details revised at 1 of 62 sitesv92
- Minor Study sites: 61 to 62v90
- Minor Study sites: 62 to 61v87
- Minor Study sites revised (62)v86
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 250 to confirmed 153
- Study sites: 67 to 62
- Minor Study sites: 68 to 67v83
- Minor Study sites: 66 to 68v82
- Minor Site details revised at 1 of 66 sitesv81
- Minor Study sites: 62 to 66v80
- Minor Site details revised at 1 of 62 sitesv79
- Minor Site details revised at 1 of 62 sitesv77
- Minor Site details revised at 1 of 62 sitesv75
- Minor Primary and study completion dates: May 24, 2025 to May 31, 2024v74
- Minor Site details revised at 3 of 62 sitesv73
- Minor Site details revised at 3 of 62 sitesv72
- Minor Study sites revised (62)v71
- Minor Study sites revised (62)v70
- Minor Interventions: Pertuzumab (Drug) to Other Combination Anti-Cancer Therapies (Drug), Pertuzumab (Drug), Trastuzumab (Drug)
- Site details revised at 1 of 62 sites
- Minor Site details revised at 3 of 62 sitesv68
- Minor Study sites: 60 to 62v67
- Minor Study sites: 58 to 60v66
- Minor Site details revised at 9 of 58 sitesv65
- Minor Site details revised at 6 of 58 sitesv64
- Minor Study sites: 56 to 58
- Primary and study completion dates: Feb 6, 2025 to May 24, 2025
- Minor Study sites: 48 to 56v62
- Minor Study sites: 46 to 48v61
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression-Free Survival
Timeframe: From date of first dose of pertuzumab in this study until the date of disease progression or death, whichever occurs first (up to approximately 10 years)
Overall Survival
Timeframe: From date of first dose of pertuzumab in this study until the date of death (up to approximately 10 years)
Number of Participants with Adverse Events by Severity, Classified According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03
Timeframe: From Baseline until 7 months after the last dose of pertuzumab (up to approximately 10 years)
Number of Participants with Adverse Events Leading to Pertuzumab Discontinuation or Dose Interruption
Timeframe: From Baseline until 7 months after the last dose of pertuzumab (up to approximately 10 years)
Number of Participants with Non-Serious Adverse Events of Special Interest (AESIs)
Timeframe: From Baseline until 7 months after the last dose of pertuzumab (up to approximately 10 years)
Left Ventricular Ejection Fraction (LVEF) Over Time
Timeframe: Baseline, every 3 treatment cycles (1 cycle is 21 days), and 28 days after last dose of pertuzumab (up to approximately 10 years)
Arms and interventions
Pertuzumab (Single-Agent or Combination Therapy)Experimental
Pertuzumab will continue to be administered as a single agent or in combination with other anti-cancer therapies at the same dose, schedule, and guidelines that were in effect at the end of the Parent study.
Drugs: Pertuzumab, Trastuzumab, Other Combination Anti-Cancer Therapies
Sites
62 sites in 15 countries
China 9, Brazil 8, Italy 7, Spain 6, Germany 5, France 4, Mexico 4, Portugal 4, Japan 3, Peru 3, South Korea 3, Russia 2, Ukraine 2, Costa Rica 1, Poland 1